Success Metrics

Active Trials

1(33%)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Detailed Status

Not yet recruiting2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

not_yet_recruiting267%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_2

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

NCT06947291

not_yet_recruitingphase_2

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

NCT06908772

not_yet_recruitingphase_2

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

NCT06525350

Clinical Trials (3)

Showing 3 of 3 trials

NCT06947291Phase 2

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Recruiting

NCT06908772Phase 2

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Not Yet Recruiting

NCT06525350Phase 2

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3